Award
Delivery Order #75N91026F00001
University of Oklahoma Awarded Contract for Triple Negative Breast Cancer Vaccines
Buyer
National Institutes of Health
Award Amount
$1,147,754.00
Ceiling
$1,147,754.00
Awarded
September 14, 2026
Period of Performance
Sep 14, 2026 – Sep 13, 2028
Identifier
75N91026F00001
NAICS
541714
This award is a delivery order contract issued to the University of Oklahoma, a research institution specializing in health sciences. The contract focuses on the development and procurement of triple negative breast cancer vaccines, aiming to advance cancer treatment options. It is part of a larger, previously awarded indefinite delivery contract supporting preclinical drug development and cancer research. This contract is significant as it contributes to the critical area of cancer vaccine innovation, potentially impacting public health outcomes. The scope covers vaccine research and development activities over a multi-year period based in Oklahoma City. The delivery order follows a competitive procurement process under the umbrella of a substantial IDIQ contract, ensuring robust research and development efforts. The contract's timeline spans from late 2026 through 2028, aligning with ongoing cancer drug development programs.
Description
TRIPLE NEGATIVE BREAST CANCER VACCINES